Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.83 |
| ▸ | BRD4 | O60885 | 11/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.55 |
| ▸ | BRD2 | P25440 | 3/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | BRD1 | O95696 | 1/20 | 0.48 |
| ▸ | CCL2 | P13500 | 1/20 | 0.48 |
| ▸ | TAF1 | P21675 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640295 | 0.91 | EGLN3 (1.00) | EGLN3BRD4EGLN1 | |
| SCHEMBL1642122 | 0.88 | EGLN3 (0.75) | EGLN3BRD4EGLN1 | |
| SCHEMBL1640549 | 0.88 | EGLN3 (0.78) | EGLN3BRD4EGLN1 | |
| SCHEMBL1642321 | 0.88 | EGLN3 (0.78) | EGLN3BRD4EGLN1 | |
| SCHEMBL13568141 | 0.87 | EGLN3 (0.78) | EGLN3BRD4EGLN1 | |
| SCHEMBL1642598 | 0.86 | EGLN3 (0.90) | EGLN3EGLN1 | |
| SCHEMBL1641992 | 0.86 | EGLN3 (0.76) | EGLN3BRD4EGLN1 | |
| SCHEMBL1642011 | 0.85 | EGLN3 (0.88) | EGLN3EGLN1 | |
| SCHEMBL1640598 | 0.85 | EGLN3 (0.71) | EGLN3BRD4EGLN1 | |
| SCHEMBL1640757 | 0.85 | EGLN3 (0.71) | EGLN3BRD4EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885BRD4 3195/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.